Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Research In Brief

This article was originally published in The Gray Sheet

Executive Summary

GE’s Mavric SL magnetic resonance technology may help find problems with hip implants. Zoll’s Lifevest wearable defibrillator performs well in registry. More research briefs.

You may also be interested in...



Transcatheter Valves At The Tipping Point

Although Edwards is the pioneer and market leader in TAVR, there is no shortage of competitors – in both the aortic and mitral valve segments – developing next-generation devices who would be happy with a fraction of this potential multibillion-dollar opportunity.

Direct Flow Medical Secures CE Mark For TAVR Device

Direct Flow Medical announced Jan. 28 the receipt of a CE mark for its transcatheter aortic heart valve system, to compete with Edwards, Medtronic among others in burgeoning market.

Research In Brief

SynCardia heart portable driver: Company has received conditional IDE approval to begin a study of its Freedom portable driver to power the CardioWest total artificial heart in bridge-to-cardiac-transplant patients. The trial, which will enroll 60 subjects, aims to demonstrate that stable CardioWest patients can manage their portable driver outside the hospital. According to SynCardia, a "major drawback" of existing technology is that patients are attached to a 418-pound driver and confined to the hospital while they await transplant. By contrast, the Freedom driver weighs 13.5 pounds and would enable patients to resume normal activities while awaiting a transplant, the firm says. The study will follow patients until transplant, 90 days after discharge, 90 days of Freedom support in the hospital or death. The Freedom driver received CE mark approval for use in Europe March 1

Topics

Related Companies

UsernamePublicRestriction

Register

MT032081

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel